Senate Aide Advises FDA Dialogue, Not Legislation, To Obtain User Fee Relief
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers seeking to revise CDRH performance goals and user fee collection targets are unlikely to find a suitable vehicle in MDUFMA "trigger-fix" legislation this fall
You may also be interested in...
User Fee Renegotiations During Trigger Fix Could Endanger Program – Schultz
CDRH is crediting the device user fee program with bringing greater visibility and leverage to the device sector and is urging cooperation to ensure the program does not lapse at the end of fiscal 2005
User Fee Renegotiations During Trigger Fix Could Endanger Program – Schultz
CDRH is crediting the device user fee program with bringing greater visibility and leverage to the device sector and is urging cooperation to ensure the program does not lapse at the end of fiscal 2005
Pediatric Device R&D, Funding Collaborations Urged By Senate HELP Staffer
FDA needs to refine its premarket path for pediatric devices, Vipul Mankad, MD, Robert Wood Johnson health policy fellow on the Senate HELP Committee, told participants at a June 24 Institute of Medicine panel meeting